Therefore, the dysregulation of VSTM2L and immune markers among cancer patients suggest a crucial role of VSTM2L in the modulation of TIME (Binnewies et al., 2018; Hinshaw and Shevde, 2019). Here, VSTM2L is linked to cancer.